After nearly four decades in the pipeline, the countries of the European Union have finally signed an agreement that is expected to lead to a system of Unitary Patents. They will have pan-European effect and an associated Unified Patent Court to enable enforcement of the Unitary Patent across Europe. If the agreement is ratified by European member states, this will represent the most radical change to the patent landscape in Europe of the past 40 years. Martin MacLean at Mathys & Squire LLP examines the issues surrounding its implementation, and how it will affect the pharmaceuticals industry.

https://international-pharma.com/wp-content/uploads/2013/06/4-What-the-unitary-patent-means-for-the-pharmaceutical-industry.pdf